Indication
Solid Advanced Tumor
1 clinical trial
1 product
Product
OSE-279Clinical trial
A Multicenter, Phase 1/2, Dose-finding and Dose Expansion Study of OSE-279, a PD-1 Blocking Monoclonal Antibody, in Subjects With Advanced Solid Tumors or LymphomasStatus: Recruiting, Estimated PCD: 2024-05-01